Overview

Modulation of the Surgical Inflammatory Response by Etoricoxib

Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that orally administered etoricoxib (COX-2) modulates prostaglandin and cytokine synthesis in the central nervous system (CNS) and in the periphery in surgical patients and thus reduces pain and suffering.
Phase:
Phase 2
Details
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Collaborators:
HELIOS Kliniken GmbH
Merck Sharp & Dohme Corp.
Rush University Medical Center
Treatments:
Etoricoxib